Harnessing Machine Learning for Accelerated Drug Discovery: Opportunities and Unmet Challenges
Pharmaceuticals · 22.05.2026 · 19 (6) · 810
DOI: 10.3390/ph19060810 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 22.05.2026. Verfasst von Mohamed El-Tanani und 5 weiteren Autor:innen. Beteiligte Einrichtung: RAK College of Pharmacy, Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah 11172, United Arab Emirates. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 176 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The process of drug discovery is one of the most expensive, time-consuming, and high-risk endeavors in modern science. Translating initial scientific insights into safe and effective therapies, supported by genomics, structural biology, and computational chemistry, typically requires more than a decade and substantial financial investment. Machine learning (ML) has emerged as a powerful tool for improving efficiency across the drug discovery pipeline. By enabling the analysis of large and complex datasets, ML supports target identification, lead discovery, optimization, and prediction of preclinical and clinical outcomes. Its integration with experimental validation and automation is illustrated by recent advances such as protein structure prediction, AI-driven antifibrotic compound discovery, and antibiotic identification. Despite these advances, significant challenges remain. Model generalizability is limited by data scarcity, heterogeneity, and hidden biases. In addition, the translation of in silico predictions into clinically validated outcomes remains a major bottleneck, and regulatory acceptance is constrained by limited model interpretability. Ethical considerations, including data privacy, equitable representation, and the potential misuse of generative models, further complicate adoption. This review examines the applications of ML across the drug discovery pipeline, with a focus on translational and regulatory considerations. It also discusses emerging directions, including hybrid physics–AI approaches, multimodal foundation models, federated learning, and explainable AI. The effective integration of ML will depend on rigorous validation, interdisciplinary collaboration, responsible data governance, and alignment with regulatory frameworks.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- RAK College of Pharmacy, Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah 11172, United Arab Emirates.
- Princess Sarvath Community College, Amman 11196, Jordan.
- Royal Cornwall Hospital Trust, NHS, Truro TR1 3LJ, UK.
- Amity Institute of Pharmacy, Amity University, Panchgaon, Gurgaon 122412, India.
- Department of Pharmacy, Jagannath University, Bahadurgarh 124507, India.
ORCID-Profile: Syed Arman Rabbani, Adil Farooq Wali, Rakesh Kumar
Zitieren
APA
El-Tanani, M., Rabbani, S. A., Wali, A. F., Muhana, F., El-Tanani, Y., & Kumar, R. (2026). Harnessing Machine Learning for Accelerated Drug Discovery: Opportunities and Unmet Challenges. Pharmaceuticals, 19(6), 810. https://doi.org/10.3390/ph19060810
Vancouver
El-Tanani M, Rabbani SA, Wali AF, Muhana F, El-Tanani Y, Kumar R. Harnessing Machine Learning for Accelerated Drug Discovery: Opportunities and Unmet Challenges. Pharmaceuticals. 2026;19(6):810. doi:10.3390/ph19060810
BibTeX
@article{ElTanani2026,
author = {El-Tanani, Mohamed and Rabbani, Syed Arman and Wali, Adil Farooq and Muhana, Frezah and El-Tanani, Yahia and Kumar, Rakesh},
title = {Harnessing Machine Learning for Accelerated Drug Discovery: Opportunities and Unmet Challenges},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {6},
pages = {810},
doi = {10.3390/ph19060810}
}
EUVIMED